CAR19-CD28-CD3z-T cells

CAR19-CD28-CD3z-T cells are autologous or allogeneic T lymphocytes genetically engineered ex vivo to express a chimeric antigen receptor (CAR) that consists of an extracellular single-chain variable fragment (scFv) specific to CD19, fused to the intracellular signaling domains of CD28 (a T-cell co-stimulatory molecule) and CD3 zeta (CD3ζ; a key T-cell receptor signaling component). Upon infusion, these CAR-T cells recognize and bind to CD19-expressing cells—commonly malignant B cells in hematologic cancers—leading to T-cell activation, proliferation, cytokine secretion, and subsequent cytotoxic lysis of target cells. Second-generation CARs, such as CAR19-CD28-CD3z, combine T-cell activation (via CD3ζ) with a co-stimulatory domain (CD28) to improve persistence, expansion, and antitumor activity compared to first-generation CARs, which lack the co-stimulatory domain. These therapies have shown high efficacy—producing complete remissions—in relapsed or refractory B-cell malignancies, but can also cause cytokine release syndrome (CRS) and neurotoxicity. The therapy is considered a form of cell therapy and immunotherapy, primarily developed and produced by leading academic medical centers and biotech companies[1][2][3][5][6].

Other names

CD19-targeted CAR T cellsCD-19-targeted CAR T cellsCD 19-targeted CAR T cellsCD19-specific CAR T cellsCD-19-specific CAR T cellsCD 19-specific CAR T cellsCD19 CAR-TCD-19 CAR-TCD 19 CAR-T